Changes in Hong Kong stocks | Junshengtai Pharmaceutical-B (02511) rose more than 5%, commercialization of T2DM indications is imminent, and HTD1801 clinical data has been announced at several international conferences

The Zhitong Finance App learned that Junshengtai Pharmaceutical-B (02511) rose by more than 5%. As of press release, it had risen 5.44% to HK$3.295, with a turnover of HK$12.095 million.

According to the news, China Securities International recently reported that in March 2026, China's State Drug Administration accepted the marketing application for HTD1801 as a new drug for the treatment of T2DM. In June 2026, phase III data for HTD1801 combined with metformin was published in “NEJM Evidence”. At the same time, Junshengtai Pharmaceutical also announced clinical research results of HTD1801 at several international conferences, demonstrating the efficacy and safety of HTD1801 in treating T2DM. In the process of awaiting approval, the company is actively exploring commercialization channels and seeking partners with strong domestic commercialization networks and expertise in the T2DM field.

The bank also stated that in July 2026, China issued the “Expert Consensus on Assessment, Diagnosis, and Treatment of Cardiovascular-Nephrometabolic Syndrome”, which first established a four-axis Chinese definition of “metabolism-cardiovascular-kidney-liver” and a phase 0-4 standard, and included MASLD as a key complication pathway. This is highly compatible with the multiple effects of HTD1801 as a single drug (hypoglycemic, lipid-lowering, kidney protection, liver protection), so the bank believes that HTD1801 has good potential for future development.